Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Nov 2022

Cao Dai, Chen Die, Xia Jiang-Nan, Wang Wen-Yan, Zhu Guo-Yuan, Chen Li-Wen, Zhang Chuantao, Tan Bo, Li Hui, Li Ying-Wei

Abstract excerpt

Lung cancer is the leading cause of cancer-related death worldwide. The development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) has brought favorable survival benefits to patients with non-small-cell lung cancer (NSCLC); unfortunately, acquired drug resistance remains a major barrier to the treatment of NSCLC. Recent studies have demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Artesunate
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Immune Checkpoint Inhibitors

Share to Molecular Docking Simulation

Share to Proteasome Endopeptidase Complex

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36271541
DOI: 10.1016/j.biopha.2022.113705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.PMID 36271541Read ↗

Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in non-small cell lung cancerSemantic proximity Read ↗

Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth.Semantic proximity Read ↗

Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.Semantic proximity Read ↗

Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagySemantic proximity Read ↗

SKIL facilitates tumorigenesis and immune escape of NSCLC via upregulating TAZ/autophagy axis.Semantic proximity Read ↗

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.Semantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid CancerSemantic proximity Read ↗

KRAS mutation promotes immune escape of lung adenocarcinoma via ZNF24/SLC7A5/PD-L1 axisSemantic proximity Read ↗

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer.Semantic proximity Read ↗

HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.